The Role of GER in Exercise Triggered Asthma

This study has been completed.
PriCara, Unit of Ortho-McNeil, Inc.
Information provided by:
University of Utah Identifier:
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted


Gastroesophageal reflux is a major contributor to exercise-triggered asthma.

Two groups of patients will be studied: those with asthma who have difficulty with exertion, those without asthma who experience difficulty with exertion. Both groups will experience gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill exam to determine their VO2 max. They will then undergo pH monitoring while exercising for 30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30 minutes) and 24-hour pH study.

Condition Intervention Phase
Drug: Achipex
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: The Role of GER in Exercise Triggered Asthma

Resource links provided by NLM:

Further study details as provided by University of Utah:

Primary Outcome Measures:
  • To determine whether patients with exercise-triggered asthma experience GER during exercise.

Secondary Outcome Measures:
  • To determine whether the exercise-induced GER within the subjects relates temporally to their exertional asthma.

Estimated Enrollment: 36
Study Start Date: October 2000
Estimated Study Completion Date: September 2005
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Exercise-triggered asthmatics – defined as asthmatics with exertion as their primary exacerbating factor and experiencing less than two episodes of classic gastroesophageal reflux a week.

Exclusion Criteria:

  • Exclusion criteria will be the following:

    1. Severe asthma (recent or repeated hospitalizations)
    2. Severe angina, cardiac arrhythmia’s, heart failure, prior MI
    3. Respiratory illness e.g. COPD
    4. Inability to receive therapy/pH probe
    5. Pregnancy
    6. Minors, prisoners, individuals unable to give informed consent
    7. Prior upper GI surgery (gastrectomy, etc)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00204672

United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
University of Utah
PriCara, Unit of Ortho-McNeil, Inc.
Principal Investigator: Kathryn A Peterson, M.D. University of Utah
  More Information

No publications provided Identifier: NCT00204672     History of Changes
Other Study ID Numbers: RAB-USA-46
Study First Received: September 12, 2005
Last Updated: September 12, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Utah:

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on November 30, 2015